About Us

MISSION AND STRATEGY

Versartis develops novel biologics with enhanced properties to provide improved therapeutic outcomes to patients with metabolic disease and endocrine disorders. 

New compounds developed by Versartis using the XTEN technology are expected to provide improved therapeutic outcomes such as enhanced efficacy, fewer side effects, prolonged half-life (up to monthly dosing), as well as low-cost production and enhanced stability.